Brief: Spero Therapeutics Q1 Operating Expenses USD 7.796 Million
13/05/2026 21:05
May 13 (Reuters) - Spero Therapeutics Q1 income from operation USD -7.538 million. Q1 net income USD -7.203 million
Recent news on Spero Therapeutics
See all newsBrief: Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Spero Therapeutics - May Offer Up To $300 Million In Securities - SEC Filing
Brief: Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., As Chief Medical Officer
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion
US FDA approves GSK's oral antibiotic for drug-resistant UTIs (updated)